皮肤癌活检后，残留肿瘤在临床上并不总是明显，这可能会促使患者质疑是否需要确定性治疗。我们调查了在进行基底基底细胞癌莫氏显微手术 (MMS) 时组织学上存在残留肿瘤的病例百分比我们检查了 2022 年 10 月至 2023 年 4 月期间对 483 例经活检证实的 BCC (n=287) 和 SCC (n=196) 进行 MMS 的病例。单级 MMS 样本被正面阶梯式切割以耗尽块体。创建了单变量和多变量逻辑回归模型。在 MMS 时，83.3% 的 BCC 和 66.8% 的 SCC 中发现了残余肿瘤 (p=0.01)。在活检后临床表现无肿瘤的患者中，68.2% 的 BCC 和 41.5% 的 SCC 中发现残留组织学肿瘤。男性 (p=0.04)、高风险部位 (p=0.002)、较小的活检尺寸 (p=0.0003) 和较大的术前尺寸 (p<0.0001) 中残留肿瘤的可能性明显更高。 单中心、回顾性队列结论：大多数 BCC 和 SCC 患者在 MMS 时有残留的组织学肿瘤，即使肿瘤在临床上并不明显。多种因素影响残留肿瘤的存在/不存在。版权所有 © 2024。由 Elsevier Inc. 出版。

Residual tumor is not always clinically apparent following biopsy of cutaneous carcinomas, which may prompt patients to question the need for definitive treatment.We investigated the percentage of cases in which residual tumor was histologically present at the time of Mohs micrographic surgery (MMS) for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) and investigated factors associated with residual tumor.We examined 483 MMS cases performed for biopsy-proven BCC (n=287) and SCC (n=196) between October 2022 and April 2023. Single-stage MMS specimens were step-sectioned en face to exhaust the block. Univariate and multivariable logistic regression models were created.Residual tumor was identified in 83.3% of BCC and 66.8% of SCC at time of MMS (p=0.01). In patients clinically appearing tumor-free following biopsy, residual histologic tumor was identified in 68.2% of BCC and 41.5% of SCC. Residual tumor was significantly more likely in men (p=0.04), high-risk sites (p=0.002), smaller biopsy sizes (p=0.0003), and larger pre-operative sizes (p<0.0001).Single center, retrospective cohort CONCLUSION: The majority of patients with BCC and SCC have residual histologic tumor at the time of MMS, oftentimes even when tumor is not clinically apparent. Multiple factors impact the presence/absence of residual tumor.Copyright © 2024. Published by Elsevier Inc.